Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.
Neuspera Medical, a US-based neuromodulation device developer based on research at Stanford University, yesterday raised $12m in additional series B capital to bring the round to its targeted $26m close.
The extension was supplied by 6 Dimensions Capital, an investment firm backed by medical research firm WuXi PharmaTech, together with Action Potential Venture Capital, Windham Venture Partners, Delta Capital, Purple Arch Ventures and unnamed investors.
The same consortium had provided an initial $14m in series B funding…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
